Prostaglandin E1 versus phentolamine/papaverine for the treatment of erectile impotence: a double-blind comparison.

Abstract

The use of intracavernous prostaglandin E1 was studied in 48 organically impotent men. Eight men with previous chemical priapism did not have chemically induced priapism at up to 4 times the minimum effective dose of prostaglandin E1. Of 15 men with arteriogenic impotence who had failed prior intracavernous phentolamine and papaverine therapy 10 had adequate erections with prostaglandin E1. A total of 25 men received intracavernous prostaglandin E1 and phentolamine plus papaverine in a double-blind fashion. Erections with prostaglandin E1 were equal or superior to those with phentolamine plus papaverine in each case.

• Authors: L M Lee, R W Stevenson, G Szasz
• Journal: The Journal of urology (J Urol) Vol. 141 Issue 3 Pg. 549-50 (Mar 1989) ISSN: 0022-5347 [Print] United States
• PMID: 2918589 (Publication Type: Clinical Trial, Comparative Study, Controlled Clinical Trial, Journal Article)

Chemical References

• Papaverine
• Alprostadil
• Phentolamine

Topics

• Alprostadil (administration & dosage, therapeutic use)
• Double-Blind Method
• Drug Therapy, Combination
• Erectile Dysfunction (drug therapy)
• Humans
• Male
• Papaverine (administration & dosage, therapeutic use)
• Penile Erection (drug effects)
• Phentolamine (administration & dosage, therapeutic use)